| 词条 | Relatlimab |
| 释义 |
| type = mab | image = | alt = | mab_type = mab | source = u | target = LAG3 | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number = 1673516-98-7 | ATC_prefix = none | ATC_suffix = | PubChem = | DrugBank = | C = 6472 | H = 9922 | N = 1710 | O = 2024 | S = 38 | molecular_weight = 145.3 g/mol | UNII = AF75XOF6W3 | KEGG = D11350 | synonyms = BMS-986016 }}Relatlimab (BMS-986016) (INN) is a monoclonal antibody designed for the treatment of melanoma.[1][2] This drug is being developed by Bristol-Myers Squibb. {{as of|2018}}, relatlimab is undergoing Phase II/III trials. References1. ^Statement On A Nonproprietary Name Adopted By The USAN Council - Relatlimab, American Medical Association. {{monoclonal-antibody-stub}}{{monoclonals for immune system}}2. ^{{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 119 | journal = WHO Drug Information | volume = 32 | issue = 2 | year = 2018 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL119.pdf | format=PDF}} 1 : Monoclonal antibodies |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。